Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 151 - 200 out of 6,113

Document Document Title
WO/2014/202703A1
The present invention relates to novel strobilurine type compounds I, processes for preparing these compounds, a use of compounds of the formula I and/or their agriculturally useful salts for controlling phytopathogenic fungi, to composi...  
WO/2014/176636A9
The invention provides compounds of Formula (I), and methods of treating or preventing a bacterial infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufactur...  
WO/2014/192823A1
Provided is a urea synthesis method of excellent reliability and productivity, the method minimizing the amount of oxygen used as an anti-corrosion agent without using a special two-phase stainless steel. In the urea synthesis device, wh...  
WO/2014/183221A1
Resveratrol analogs and their use to inhibit Kv1.5 channels are provided. The resveratrol analogs are useful in the treatment of atrial arrhythmias, including atrial fibrillation (AF). Exemplary resveratrol analogs are compounds of gener...  
WO/2014/184116A1
The invention relates to new carbodiimides having terminal urea and/or urethane groups of formula (I), wherein R can be the same or different and is selected from the group of the -NHCONHR', -NHCONR'R'', and -NHCOOR''' residues. The inve...  
WO/2014/184248A2
Compounds of Formula (I), pharmaceutically acceptable salts thereof, diastereomers, enantiomers, or mixtures thereof: wherein R1, R2, R3, X, Yn and A are as defined in the specification, as well as pharmaceutical compositions including t...  
WO/2014/176636A1
The invention provides compounds of Formula (I), and methods of treating or preventing a bacterial infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufactur...  
WO/2014/174745A1
Compared to a traditional Eg5 (KSP: kinesin spindle protein) inhibitor, this water-soluble polycyclic compound or a pharmacologically acceptable salt thereof has a greater solubility in an aqueous solvent and has Eg5 inhibitory activity ...  
WO/2014/158654A1
Compounds of formula (II): wherein A, R1, R2, R5 and R13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well...  
WO/2014/150646A1
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, vi...  
WO/2014/146995A1
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2014/118556A3
Sphingosine 1-phosphate (S1P) is involved in hyper-proliferative diseases, such as cancer and vascular remodeling in pulmonary arterial hypertension. Inhibitors of sphingosine kinase 1 and 2 (SK1 and SK2), which catalyze the synthesis of...  
WO/2014/140238A1
The invention relates to a modified allophanate compound bearing acrylate functions, resulting from the reaction of a particular allophanate with an ester from the reaction between an acid selected from acrylic acid and methacrylic acid ...  
WO/2014/143561A1
Compounds of formula (I): where R1, R2, R3, R4a, R4b, R5, R6 and R7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may b...  
WO/2014/111102A3
The present invention relates to a composition that is effective as a rheology additive and contains 15 - 95% by weight of an oxygen compound (A), 5 - 75% by weight of a urea compound (B), 0 - 50% by weight of an ionogenic compound (C) a...  
WO/2014/138452A1
The present invention relates to compounds of formula I or a pharmaceutically acceptable salts thereof; wherein the variables R1-R5, Ar1, and X are as defined herein. The compounds are capable of modulating tyrosine kinase signal transdu...  
WO/2014/114649A1
The present invention provides a small molecule inhibitor for adipose triglyceride lipase (ATGL) with the molecule having IC 50 concentrations in the submicromolar range. The inhibitor has the basic structure (I) as disclosed herein and ...  
WO/2014/113607A1
Disclosed herein inter alia are compositions and methods useful in the treatment of infectious diseases and exposure to toxins.  
WO/2014/078895A1
The present invention relates to new fatty acid analogues and to their use in cancer therapy, including antimetastatic therapy.  
WO/2014/065327A1
[Problem] To provide an acrylic or methacrylic compound having a hydroxyl group, and a method for producing the same. [Solution] An acrylic or methacrylic compound having a hydroxyl group represented by formula (1). (In the formula, R1 r...  
WO/2012/116176A3
Compounds of Formula (I), known as asymmetric ureas, are useful for preventing and/or treating diseases that are pathophysiologic ally related to the ghrelin receptor in a subject. Method of treating a disease that is mediated by the ghr...  
WO/2014/048547A1
The present invention relates to alpha hydroxy amides including compounds of formula (I) and related compounds and their use in the prophylaxis and treatment of inflammatory disorders and diseases, wherein T1, T2, W and Rw has the meanin...  
WO/2014/048700A1
The invention relates to a composition comprising components which are selected from A) at least one compound containing at least one carbodiimide group, B) at least one compound containing at least one carboxylic anhydride group, C) opt...  
WO/2013/190509A3
Processes for preparing intermediates of Boceprevir and their use in preparation of Boceprevir or its pharmaceutically acceptable salts are provided.  
WO/2014/026845A1
The present invention relates to carbamates of formula (I), wherein the variables are defined according to the description, as well as to a process for manufacturing carbamates of formula (I), and to the use of carbamates of formula (I) ...  
WO/2014/022975A1
Provided in the present invention are N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methyl phenyl)carbamide and a preparation method for the intermediate thereof. In particular, provided in the present invention is a method for pr...  
WO/2014/016745A1
The invention relates to a process comprising: reacting isobutyraldehyde with an aqueous solution of urea in the presence of a phase transfer catalyst to form isobutylidene diurea. Preferably, the phase transfer catalyst is a quaternary ...  
WO/2013/175347A3
Disclosed are the compounds of Formula (I) or pharmaceutical acceptable salts thereof, the pharmaceutical compositions comprising an effective amount of compounds of Formula (I), and methods for the treatment of respiratory disorders.  
WO/2013/181697A1
The present invention relates to compounds that can be used link substrates to molecules, typically for biological applications such as imaging and the like. The compounds contain a cyclooctyne which is joined, via a linking group, to a ...  
WO/2013/174947A1
The present invention relates to inhibitors of the activity of Complex (III) of the mitochondrial electron transport chain and use thereof in treatment and/or prevention of cancers presenting tumour-initiating cells. The present inventio...  
WO/2013/152223A2  
WO/2013/141163A1
Provided is a blocked isocyanate from which the isocyanate group can be easily regenerated even when heated at a low temperature for a short time. The blocked isocyanate is a compound having a group represented by formula (1) or (1'). (X...  
WO/2013/134467A1
Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.  
WO/2013/130849A1
This invention relates to novel substituted dioxopiperidinyl phthalimide derivatives and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the us...  
WO/2013/129121A1
The problem to be solved by the present invention is to provide a liquid crystal composition which exhibits little haziness when subjected to liquid crystal alignment and made into a film, and with which cissing can be inhibited when a f...  
WO/2013/127841A1
The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and X are defined in the detailed description and claims. In addition, the present invention relates to method...  
WO/2013/115334A1
An embodiment of the present invention is a separating agent wherein a group represented by chemical formula (1) or a group represented by chemical formula (2) is introduced to the surface.  
WO/2013/096223A1
Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds a...  
WO/2013/091285A1
Provided are a urea compound having a structure as represented by general formula I, preparation method thereof, pharmaceutical composition containing the compound, and uses thereof in the preparation of drugs for treating inflammatory r...  
WO/2013/086397A1
The present invention relates to compounds, to pharmaceutical compositions comprising the compounds, to a process for making the compounds and to the use of the compounds in therapy. More particularly, it relates to certain glucokinase a...  
WO/2013/082302A1
The present invention provides an Agomelatine-urea complex, and a specific crystalline form thereof.  
WO/2013/070600A1
The present invention relates to novel aryl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) recep...  
WO/2013/070118A1
This invention relates to novel substituted 4,5-diamino-3-alkyloxy- cyclohex-1-ene carboxylic acids, esters thereof or pharmaceutically acceptable salts and/or hydrates, to novel antiviral medicines - inhibitors of the activity of neuram...  
WO/2013/064029A1
Provided in the present invention are a benzoylurea derivative of formula (I) with anticancer activity or the pharmaceutically acceptable salt or prodrug thereof, and the preparation of such a derivative and the use thereof in preparing ...  
WO/2013/062947A1
The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide ...  
WO/2013/062028A1
Provided are a novel compound having an antiviral effect, particularly HIV replication-inhibiting activity, and a medical drug, particularly an anti-HIV drug, containing the same. The compound is represented by Formula (I) (where the bro...  
WO/2013/060889A1
The invention relates to oseltamivir derivatives as influenza neuraminidase inhibitors for treating influenza infections and to a method for producing said compounds.  
WO/2013/056559A1
Provided are a modified diphenylmethane diisocyanate (MDI) biuret curing agent and preparation method thereof, the curing agent being prepared by reacting dibasic alcohol, water and MDI in an organic solvent; the molar ratio between the ...  
WO/2013/030358A1
The invention relates to 4-aminonaphthalene-2-carboxylic acids and 1-amino- isoquinoline-3-carboxylic acids as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compou...  
WO/2013/017714A1
The present invention relates to a family of new compounds of general formula (I) that act as low-molecular-weight organogels for a wide variety of solvents and that provide a gel that is very stable at high temperatures. General formula...  

Matches 151 - 200 out of 6,113